Trials / Completed

CompletedNCT04769479

A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Tablet Formulations in Healthy Subjects

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 14 (actual)

Sponsor: Eidos Therapeutics, a BridgeBio company · Industry
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Accepted

Summary

This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.

Detailed description

It is planned to enroll 14 subjects who will receive single oral doses of active IMP in a sequential manner over 5 periods, with a minimum of 7days between dosing in each period.

Conditions

Amyloidosis

Interventions

Type	Name	Description
DRUG	acoramidis	acoramidis

Timeline

Start date: 2021-03-28
Primary completion: 2021-08-04
Completion: 2021-09-03
First posted: 2021-02-24
Last updated: 2024-09-19

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04769479. Inclusion in this directory is not an endorsement.